Sunesis pares staff in cost-cutting move

Sunesis Pharmaceuticals is paring 35 workers, or 25 percent of its staff, in an effort to pare out $10 million in costs. Research and general administrative areas will be cut the most as the developer concentrates on advancing its lead therapy, SNS-595 for leukemia and ovarian cancer. Sunesis had $65.2 million in cash on hand at the end of June.

- see the announcement on the cuts

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.